Cannabidiol attenuates the appetitive effects of Δ9- tetrahydrocannabinol in humans smoking their chosen cannabis

Neuropsychopharmacology

Volumn 35, Issue 9, 2010, Pages 1879-1885

  Morgan, Celia J A ^a   Freeman, Tom P ^a   Schafer, Gráinne L ^a   Curran, H Valerie ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

addiction; attention bias; cannabidiol; cannabis; dependence; THC

Indexed keywords

CANNABIDIOL; CANNABIS; DRONABINOL; PSYCHEDELIC AGENT;

ADOLESCENT; ADULT; APPETITE; ARTICLE; CANNABIS ADDICTION; CANNABIS SMOKING; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FOOD; HUMAN; INTOXICATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REINFORCEMENT; SALIVA ANALYSIS; SELF CONCEPT; STIMULATION; ANALYSIS OF VARIANCE; CLINICAL TRIAL; DECISION MAKING; DRUG EFFECTS; DRUG THERAPY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NEUROPSYCHOLOGICAL TEST; PROCEDURES; PSYCHOLOGY; REACTION TIME; URINE; YOUNG ADULT;

ADOLESCENT; ANALYSIS OF VARIANCE; APPETITIVE BEHAVIOR; CANNABIDIOL; CHOICE BEHAVIOR; CHROMATOGRAPHY, LIQUID; FEMALE; HALLUCINOGENS; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MASS SPECTROMETRY; NEUROPSYCHOLOGICAL TESTS; REACTION TIME; TETRAHYDROCANNABINOL; YOUNG ADULT; DRONABINOL;

EID: 77954761129     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.58     Document Type: Article

References (37)

1. Berridge KC, Robinson TE, Aldridge JW (2009). Dissecting components of reward: 'liking', 'wanting', and learning. Curr Opin Pharmacol 9: 65-73.
2. Bitencourt RM, Pamplona FA, Takahashi RN (2008). Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsycho- pharmacol 18: 849-859.
3. Chait LD, Zacny JP (1992). Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans. Psycho- pharmacology (Berl) 107: 255-262.
4. Chopra IC, Chopra RN (1957). The use of cannabis drugs in India. Bull Narc 9: 4-29.
5. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370: 1706-1713.
6. Cooper ZD, Haney M (2009). Actions of delta-9-tetrahydrocanna- binol in cannabis: relation to use, abuse, dependence. Int Rev Psychiatry 21: 104-112.
7. Curran HV, Brignell C, Fletcher S, Middleton P, Henry J (2002). Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl) 164: 61-70.
8. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558-1572.
9. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T et al (2008). Blunted psychotomimetic and amnestic effects of Delta-9- tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33: 2505-2516.
10. Duka T, Townshend JM (2004). The priming effect of alcohol preload on attentional bias to alcohol-related stimuli. Psychopharmacology (Berl) 176: 353-361.
11. EMCDDA (2006). Annual Report 2006: The State of the Drugs Problem in Europe. European Monitoring Centre for Drugs and Drug Addiction: Lisbon. Pamphlet.
12. Fadardi JS, Cox WM (2009). Reversing the sequence: reducing alcohol consumption by overcoming alcohol attentional bias. Drug Alcohol Depend 101: 137-145.
13. Field M, Eastwood B, Bradley BP, Mogg K (2006). Selective processing of cannabis cues in regular cannabis users. Drug Alcohol Depend 85: 75-82.
14. Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W et al (1995). The severity of dependence scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90: 607-614.
15. Guimares FS, Chiaretti TM, Graeff FG (1990). Antianxiety effects of cannabidiol in the elevated plus-maze. Psychopharmacology 100: 558-559.
16. Hardwick S, King LA (2008). Home Office Cannabis Potency Study. Home Office Scientific Development Branch: St Albans. Report.
17. Heishman SJ, Evans RJ, Singleton EG, Levin KH, Copersino ML, Gorelick DA (2009). Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend 102: 35-40.
18. Hermann D, Sartorius A, Welzel H, Walter S, Skopp G, Ende G et al (2007). Dorsolateral prefrontal cortex N-acetylaspartate/ total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry 61: 1281-1289.
19. Kelly TH, Foltin RW, Emurian CS, Fischman MW (1997). Are choice and self-administration of marijuana related to delta 9- THC content? Exp Clin Psychopharmacol 5: 74-82.
20. Kirkham TC (2009). Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry 21: 163-171.
21. Mahler SV, Smith KS, Berridge KC (2007). Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuro- psychopharmacology 32: 2267-2278.
22. Marissen MA, Franken IH, Waters AJ, Blanken P, van den BW, Hendriks VM (2006). Attentional bias predicts heroin relapse following treatment. Addiction 101: 1306-1312.
23. Morgan CJA, Rees H, Curran HV (2008). Attentional bias to incentive stimuli in frequent ketamine users. Pschol Med 38: 1331-1340.
24. Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R (2004). Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology 175: 360-366.
25. Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
26. Ren Y, Whittard J, Higuera-Matas A, Morris CV, Hurd YL (2009). Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci 29: 14764-14769.
27. Robinson TE, Berridge KC (1993). The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18: 247-291.
28. Robinson TE, Berridge KC (2001). Incentive-sensitization and addiction. Addiction 96: 103-114.
29. Robinson TE, Berridge KC (2003). Addiction. Annu Rev Psychol 54: 25-53.
30. Robinson TE, Berridge KC (2008). Review. The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc Lond B Biol Sci 363: 3137-3146.
31. Rodriguez dF, Navarro M, Gomez R, Escuredo L, Nava F, Fu J. et al (2001). An anorexic lipid mediator regulated by feeding. Nature 414: 209-212.
32. SolowijN, Hall W, Lee N (1992). Recreational MDMA use in Sydney: a profile of 'Ecstasy' users and their experience with the drug. Br J Addict 87: 1161-1172.
33. Taylor D (2009). Withdrawal of Rimonabant-walking the tightrope of 21st century pharmaceutical regulation? Curr Drug Saf 4: 2-4.
34. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL (2008). Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)- tetrahydrocannabinol. Drug Alcohol Depend 94: 191-198.
35. Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH (2003). Attentional bias predicts outcome in smoking cessation. Health Psychol 22: 378-387.
36. Wechsler D (2001). Wechsler Test of Adult Reading. Psychological Corportation: San Antonio, TX.
37. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS (2006). Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39: 421-429.